Hey mate, please hang around. Appreciate your input. Agree re...

First 29 Last

Share
Profile

Follow
bernsta

3,685 Posts.

108

12/09/18

22:58

Post #: 35562332
Share

Originally posted by noob_75 ↑

I don't need to google it to read side effects (not affects). I have used the drug in hundreds of patients to understand how effective it is, and how to use it to minimise the potential and guaranteed side effects.

The data so far, shows no efficacy yet, so you cannot compare the two. You have to understand why acne occurs and what certain medications do, and what they are trying to target in the pathological process in order to understand why I have said it won't be as effective as isotretinoin (proper drug name - as opposed to brand names accutane, roaccutane, oratane etc...). There are topical retinoids already used to treat acne (topical/cream version of isotretinoin) which are partially effective in mild-moderate acne, but the only medication that works well for severe nodulocystic acne is isotretinoin. Topical products unfortunately don't work for this type of acne.... BOT may have a great product in the making, and I hope they do (as I hold shares), but I just want to keep a reality check on things for those that are pumping it up for guaranteed disappointment.

On HC, anyone that has a contrary view to the SP going up for whatever reason seems to get attacked, but I'm not downramping.... as I own the stock and possibly keen to get more in the future. There is no data out yet, so we just don't know. If the double blind study is a failure (no statistical significance between placebo and treatment arm), the SP will crash, and that is also a distinct possibility. I hope that not to be the case, and then if they really believe in their product they would do a head to head trial with current topical therapies used on the market (this is risky if it isn't better than current options).

Big market as stated, and hence if shown to be as effective or more effective than current topical therapies that would be enough for a massive company, and massive SP. Just don't get your hopes up that it is going to replace oral isotretinoin.... I stand to be corrected if they ever compared the two (very unlikely to happen).

Expand

Hey mate, please hang around. Appreciate your input.

Agree re contrarian views on HotCopper - they are often ridiculed.

Have you any comment on the effectiveness of the topical in phase 1 acne trials that were more effective than companies with topical products which have market caps 10 times what this company has?

I would imagine that surely this would command a share price much higher.

Also surely the side effects of Botanix are much more minimal then oral meds? I remember taking minomycin as a teenager. I was off chops on that stuff.

Cheers

BOT Price at posting: 9.6¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Dreadnought achieves 84% indicated resource at Star of Mangaroon

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

There are more pages in this discussion • 3 more messages in this thread...

First 29 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 35.5¢		Change 0.020(5.97%)		Mkt cap ! $707.4M

Open	High	Low	Value	Volume
33.5¢	36.0¢	33.3¢	$2.622M	7.530M

Buyers (Bids)

No.	Vol.	Price($)
5	106888	35.0¢

Sellers (Offers)

Price($)	Vol.	No.
35.5¢	462320	5

View Market Depth

No.	Vol.	Price($)
11	423267	0.105
23	1189777	0.100
1	10111	0.099
1	50000	0.098
1	50000	0.097

Price($)	Vol.	No.
0.110	555657	10
0.115	560304	6
0.120	829451	14
0.125	1083838	12
0.130	498290	12

Last trade - 16.10pm 26/11/2024 (20 minute delay)

BOT (ASX) Chart

Hey mate, please hang around. Appreciate your input. Agree re...

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Dreadnought achieves 84% indicated resource at Star of Mangaroon

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Buyers (Bids)

Sellers (Offers)